NCT06211153View on ClinicalTrials.gov

Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

CompletedOBSERVATIONAL
Enrollment

31

Participants

Timeline

Start Date

December 31, 2021

Primary Completion Date

December 15, 2022

Study Completion Date

December 15, 2022

Conditions
Chronic Myeloid Leukemia With T315I Mutation
Trial Locations (1)

4056

Novartis, Basel

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY

NCT06211153 - Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP) | Biotech Hunter | Biotech Hunter